Results 1 to 10 of about 345,374 (311)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus [PDF]

Lupus Science and Medicine, 2020
Objective Persistent positivity for lupus anticoagulant has been associated with an increased risk of thrombosis among patients with SLE. Persistent positivity is often defined as having two positive assessments separated by more than 90 days.
Laurence S Magder, Mertcan Avci
doaj   +3 more sources

Exogenous Magnesium Chloride Reduces the Activated Partial Thromboplastin Times of Lupus Anticoagulant-Positive Patients. [PDF]

PLoS ONE, 2016
The activated partial thromboplastin time (APTT) assay is a basic hemostatic assay based on the time it takes for clots to form in plasma samples after the addition of calcium chloride. It is used to screen for various coagulation disorders.
Takayoshi Tokutake, Hisami Baba, Yuji Shimada, Wataru Takeda, Keijiro Sato, Yuki Hiroshima, Takehiko Kirihara, Ikuo Shimizu, Hideyuki Nakazawa, Hikaru Kobayashi, Fumihiro Ishida   +10 more
doaj   +4 more sources

Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis [PDF]

Journal of Thrombosis and Haemostasis, 2020
This guidance focuses on methodological aspects of lupus anticoagulant (LA) testing, as well as interpretation of results for clinicians. The main changes in how to test for LA compared with the International Society on Thrombosis and Haemostasis ...
K. Devreese, P. D. de Groot, B. de Laat, D. Erkan, E. Favaloro, I. Mackie, M. Martinuzzo, T. Ortel, V. Pengo, J. Rand, A. Tripodi, D. Wahl, H. Cohen   +12 more
semanticscholar   +2 more sources

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action [PDF]

Journal of Thrombosis and Haemostasis, 2021
The presence of lupus anticoagulant (LA) is an independent risk factor for thrombosis. This laboratory phenomenon is detected as a phospholipid‐dependent prolongation of the clotting time and is caused by autoantibodies against beta2‐glycoprotein I ...
T. Noordermeer, J. Molhoek, R. Schutgens, Silvie A. E. Sebastian, Sandra Drost-Verhoef, A. V. van Wesel, P. D. de Groot, J. Meijers, R. Urbanus   +8 more
semanticscholar   +2 more sources

Prothrombin Is Responsible for the Lupus Cofactor Phenomenon in a Patient with Lupus Anticoagulant/Hypoprothrombinemia Syndrome

TH Open, 2020
Lupus anticoagulant is a misnomer as it is commonly associated with thromboembolic events. In few cases, the name retains its literal meaning when it characterizes patients with a bleeding disorder.
Vittorio Pengo, Lorena Zardo, Maria Grazia Cattini, Elisa Bison, Elena Pontara, Sara Altinier, Chunyan Cheng, Gentian Denas   +7 more
doaj   +2 more sources

Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants. [PDF]

Res Pract Thromb Haemost, 2022
Lupus anticoagulants (LA) are one laboratory criterion for classification of antiphospholipid syndrome, with presence of vascular thrombosis and/or pregnancy/fetal morbidity being clinical criteria.
Favaloro EJ, Pasalic L.
europepmc   +2 more sources

Clinical and laboratory practice for lupus anticoagulant testing : an International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey [PDF]

Journal of Thrombosis and Haemostasis, 2019
Background Current guidelines have contributed to more uniformity in the performance and interpretation of lupus anticoagulant (LA) testing. However, points to reconsider include testing for LA in patients on anticoagulation, cut-off values, and ...
Cohen, Hannah, Devreese, Katrien, Mackie, Ian J., the International Society for Thrombosis and Haemostasis Scientific and Standardization Committee for Lupus Anticoagulant/Antiphospholipid Antibodies, [missing]   +3 more
core   +3 more sources

Lupus anticoagulant hypoprothrombinemia syndrome: A case report [PDF]

Clinical Case Reports, 2023
Lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare entity associated with an increased risk of hemorrhage. Corticosteroids have been used in its treatment with favorable results.
Natalia Acedo, Alejandro Alonso, Eliana Samantha Feijoó, Cristina García, Ana M. Ortiz, Adrián Alegre   +5 more
doaj   +2 more sources

Successful treatment of lupus anticoagulant hypoprothrombinemia syndrome with rituximab [PDF]

Thrombosis Journal, 2023
Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder secondary to development of antibodies against prothrombin protein, in the presence of antiphospholipid antibodies.
Sanober Nusrat, Sayani Tewari, Osman Khan   +2 more
doaj   +2 more sources

Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China [PDF]

Research and Practice in Thrombosis and Haemostasis
Background: Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder characterized by the presence of lupus anticoagulant (LA) and acquired hypoprothrombinemia.
Dandan Tian, Junfeng Zhang, Jintu Lou, Xuejun Chen, Juan Liang, Xiaojun Xu, Hui Gao, Wenjian Nie, Qing Ye, Hongqiang Shen   +9 more
doaj   +2 more sources